Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Bowers, Laura W ^a   Cavazos, David A ^a   Maximo, Ilane X F ^a   Brenner, Andrew J ^a,b   Hursting, Stephen D ^a,c   DeGraffenried, Linda A ^a,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Akt; breast cancer; crosstalk; estrogen receptor; MAPK; obesity

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; SOMATOMEDIN C RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL STRAIN MCF 7; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OBESITY; POSTMENOPAUSE; SERUM; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OBESITY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 84880336001     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3453     Document Type: Article

References (56)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307:491-497. 10.1001/jama.2012.39, 22253363.
2. World Health Statistics 2012. , http://www.who.int/gho/publications/world_health_statistics/2012/en/
3. Trentham-Dietz A, Newcomb PA, Storer BE, Longnecker MP, Baron J, Greenberg ER, Willett WC. Body size and risk of breast cancer. Am J Epidemiol 1997, 145:1011-1019. 10.1093/oxfordjournals.aje.a009057, 9169910.
4. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003, 95:1218-1226.
5. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:454-463. 10.1158/1055-9965.EPI-10-0974, 3064558, 21364029.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638. 10.1056/NEJMoa021423, 12711737.
7. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 1992, 116:26-32. 10.7326/0003-4819-116-1-26, 1727092.
8. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer?. Breast Cancer Res Treat 2008, 111:329-342. 10.1007/s10549-007-9785-3, 17939036.
9. Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wöckel A. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 2011, 131:925-931.
10. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002, 20:1128-1143. 10.1200/JCO.20.4.1128, 11844838.
11. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010, 28:3411-3415. 10.1200/JCO.2009.27.2021, 20547990.
12. Schmid P, Possinger K, Bohm R, Chaudri H, Verbeek A, Grosse Y, Luftner D, Petrides P, Sezer O, Wischnewsky M. Body mass as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. Proceedings of the Annual Meeting of the American Society of Clinical Oncology: 20-23 May 2000; New Orleans 2000, 19.
13. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, Perri MG, Stanczyk FZ, Van Horn L, Wang CY. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 2006, 14:1662-1677. 10.1038/oby.2006.191, 17030978.
14. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995, 87:1297-1302. 10.1093/jnci/87.17.1297, 7658481.
15. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989, 129:1120-1131.
16. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996, 32A:404-412.
17. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997, 79:730-739. 10.1002/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0, 9024711.
18. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247. 10.1146/annurev-med-070909-182917, 3656649, 20887199.
19. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
20. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997, 21:355-359. 10.1038/sj.ijo.0800412, 9152736.
21. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factor in human obesity. Metabolism 1995, 44:37-44.
22. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006, 74:443-477.
23. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JA. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1:1155-1161. 10.1038/nm1195-1155, 7584987.
24. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006, 17:328-336. 10.1016/j.tem.2006.08.006, 16956771.
25. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137. 10.1016/S0304-3835(03)00159-9, 12767520.
26. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007, 120:796-805. 10.1002/ijc.22336, 17096325.
27. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cells-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 2012, 113:3363-3370. 10.1002/jcb.24212, 22644871.
28. Dieudonne MA, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002, 293:622-628. 10.1016/S0006-291X(02)00205-X, 12054648.
29. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffma B, Hood N. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002, 74:65-76. 10.1023/A:1016075709022, 12150454.
30. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009, 27:3437-3444. 10.1200/JCO.2008.18.9068, 2717751, 19470939.
31. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010, 11:1133-1146. 10.2174/138945010792006799, 20545607.
32. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 2012, 30:164-171. 10.1200/JCO.2011.36.2723, 22162568.
33. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012, 135:639-646. 10.1007/s10549-012-2170-x, 22847511.
34. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012, 30:2844-2852. 10.1200/JCO.2011.39.7505, 22689798.
35. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128:783-794. 10.1007/s10549-011-1612-1, 21655990.
36. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011, 29:585-593. 10.3109/07357907.2011.616252, 21936625.
37. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011, 103:1461-1468. 10.1093/jnci/djr291, 3186780, 21813413.
38. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 2010, 119:137-144. 10.1007/s10549-009-0507-x, 19728082.
39. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004, 150:161-171. 10.1530/eje.0.1500161, 14763914.
40. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008, 113:2385-2397. 10.1002/cncr.23875, 18819158.
41. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog 2013, 52:446-458. 10.1002/mc.21878, 22290600.
42. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer 2012, 19:57-68. 10.1530/ERC-11-0213, 22143497.
43. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA 2004, 101:2076-2081. 10.1073/pnas.0308334100, 357054, 14764897.
44. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol Endocrinol 2002, 16:116-127. 10.1210/me.16.1.116, 11773443.
45. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407:538-541. 10.1038/35035131, 2670482, 11029009.
46. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001, 20:6050-6059. 10.1093/emboj/20.21.6050, 125704, 11689445.
47. Altschuler D, Yamamoto K, Lapetina EG. Insulin-like growth factor-1-mediated association of p85 phosphatidylinositol 3-kinase with pp 185: requirement of SH2 domains for in vivo interaction. Mol Endocrinol 1994, 8:1139-1146. 10.1210/me.8.9.1139, 7838146.
48. Thorne C, Lee AV. Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Dis 2003, 17:105-114.
49. Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, ORegan RM, Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008, 68:9712-9722. 10.1158/0008-5472.CAN-08-1952, 3180854, 19047149.
50. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494. 10.1126/science.270.5241.1491, 7491495.
51. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141:4503-4511. 10.1210/en.141.12.4503, 11108261.
52. Hoeflich KP, OBrien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
53. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 2006, 66:10162-10170. 10.1158/0008-5472.CAN-05-4111, 17047081.
54. Miller TW, Hennessy BT, Gonzale-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3-kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413. 10.1172/JCI41680, 2898598, 20530877.
55. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328. 10.1093/annonc/mdm170, 17693645.
56. Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, Harris AL, Martin LA, Andreis D, Bottini A, Generali D, Petronini PG. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 2012, 323:77-87. 10.1016/j.canlet.2012.03.034, 22484466.